



OPEN ACCESS

EDITED BY

Roberto Tonelli,
University of Modena and Reggio Emilia, Italy

REVIEWED BY

Giulia Bruzzi,
University Hospital of Modena, Italy
Joanna Przybek-Mita,
University of Rzeszow, Poland

*CORRESPONDENCE

Daniele Melo Sardinha
✉ danielle-vianna20@hotmail.com

RECEIVED 03 April 2025

ACCEPTED 08 July 2025

PUBLISHED 23 July 2025

CITATION

Sousa VAA, Ferreira DNdS, Mendonça GVG, Marinho RL, Andrade NCO, Soares TdN, Silva MJA, Lobato DdC, dos Santos SdS, Rodrigues YC, Sardinha DM and Lima LNGC (2025) Factors associated with medical device-related pressure injury in an intensive care unit in the Amazon region during the COVID-19 pandemic: retrospective cohort. *Front. Med.* 12:1605584. doi: 10.3389/fmed.2025.1605584

COPYRIGHT

© 2025 Sousa, Ferreira, Mendonça, Marinho, Andrade, Soares, Silva, Lobato, dos Santos, Rodrigues, Sardinha and Lima. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Factors associated with medical device-related pressure injury in an intensive care unit in the Amazon region during the COVID-19 pandemic: retrospective cohort

Vitória Alice Alencar Sousa¹, Daniele Nunes da Silva Ferreira¹, Giovana Vitória Guimarães Mendonça¹, Rebecca Lobato Marinho², Natasha Cristina Oliveira Andrade², Tamires de Nazaré Soares², Marcos Jessé Abrahão Silva^{2,3}, Diana da Costa Lobato², Suziane do Socorro dos Santos², Yan Corrêa Rodrigues^{2,3,4}, Daniele Melo Sardinha^{2,3,4*} and Luana Nepomuceno Gondim Costa Lima^{2,3,4}

¹Secretaria Municipal de Saúde (SESAU), Benevides, Brazil, ²Programa de Pós-Graduação em Biologia Parasitária na Amazônia, Universidade do Estado do Pará and Instituto Evandro Chagas (PPGBPA/UEPA/IEC), Belém, Brazil, ³Seção de Bacteriologia e Micologia, Instituto Evandro Chagas (SABMI/IEC), Ananindeua, Brazil, ⁴Programa de Pós-Graduação em Epidemiologia e Vigilância em Saúde, Instituto Evandro Chagas (PPGEVS/IEC), Ananindeua, Brazil

Medical device-related pressure injuries (MDRPIs) pose a serious public health challenge, particularly in intensive care settings during the COVID-19 pandemic. This retrospective cohort study aimed to characterize the profile and identify risk and protective factors for MDRPIs among adult ICU patients in a metropolitan region of the Amazon between January 2021 and December 2022. We reviewed 603 medical records—31 patients (5.1%) developed MDRPIs and 572 did not—and applied chi-square tests, normality assessments, Mann–Whitney U-tests, binary logistic regression, and Kaplan–Meier survival analysis. Ethical approval was obtained from the Fundação Hospital de Clínicas Gaspar Viana Ethics Committee (approval no. 5,991,542). Independent risk factors for MDRPIs included chronic obstructive pulmonary disease (OR 19.33; 95% CI 2.92–127.73; $p = 0.002$), orotracheal tube use (OR 19.00; $p = 0.002$), nasal catheter use (OR 3.33; 95% CI 1.32–8.40; $p = 0.011$), and longer hospital stay (OR 1.09 per day; 95% CI 1.05–1.12; $p < 0.001$). Protective factors were systemic arterial hypertension (OR 0.22; 95% CI 0.08–0.58; $p = 0.009$), higher Braden scale scores (OR 0.22 per point; 95% CI 0.08–0.58; $p = 0.002$), and invasive arterial blood pressure monitoring (OR 0.14; 95% CI 0.03–0.79; $p = 0.025$). Survival analysis demonstrated that patients with MDRPIs had significantly longer hospital stays and higher mortality rates (Breslow $p = 0.007$; log-rank $p = 0.041$; Tarone–Ware $p = 0.011$). This first study of MDRPIs in the Amazon region highlights key modifiable factors and underscores the need for enhanced nursing protocols and working conditions to prevent device-related pressure injuries in critical care. These findings can guide continuing education initiatives and policy development in critical care nursing.

KEYWORDS

epidemiology, pressure ulcer medical, medical devices, adult intensive care units, associated factor

1 Introduction

Medical device-related pressure injuries (MDRPIs) constitute a significant public health concern (1). The etiology of these injuries is multifactorial, involving damage to integumentary tissues caused by prolonged pressure. The design, configuration, and positioning of medical devices used for therapeutic purposes significantly influence the development of these injuries (2–4). Unfortunately, MDRPIs have become increasingly common in hospital settings, particularly among vulnerable patients admitted to Intensive Care Units (ICUs) (5). MDRPIs have a dual impact: they cause physical and psychological distress for patients and impose substantial costs on healthcare institutions and patients' families. They have been associated with increased morbidity and mortality rates and are considered indicators of suboptimal healthcare quality (6).

The COVID-19 pandemic has exacerbated the incidence of MDRPIs due to increased ICU admissions and weakened healthcare services (7). Consequently, there has been a heightened use of medical devices in critical care, further contributing to MDRPI prevalence (2).

Existing literature highlights that ICU patients are especially susceptible to MDRPIs due to risk factors such as prolonged hospital stays, frequent use of medical devices, and hemodynamic instability related to medication use (8, 9). Additionally, MDRPIs can result from healthcare professionals prioritizing the treatment of acute illnesses or other clinical conditions over comprehensive skin care (8, 10). Notably, incorrect device use, inadequate positioning or securing of equipment, improper selection of medical devices, insufficient skin assessment, and device malfunction can significantly increase the risk of MDRPIs (11).

In Brazil, the National Health Surveillance Agency (ANVISA) maintains the Health Surveillance Notification system (NOTIVISA), enabling the reporting of adverse events, including MDRPIs, and technical complaints in hospitalized patients. Data collected via NOTIVISA support the implementation of measures aimed at health protection and promotion (12). However, surveillance efficacy is compromised due to incomplete reporting forms, resulting in underreporting and a lack of accurate data.

Currently, no studies have been conducted in the Brazilian Amazon region to investigate the profile and associated factors of ICU patients affected by MDRPIs. Given their clinical characteristics, these patients are particularly vulnerable to injuries from medical devices.

This study aims to identify the patient profile and associated factors related to medical device-induced pressure injuries in an adult ICU within a metropolitan area of the Amazon during the COVID-19 pandemic.

2 Materials and methods

2.1 Type of study and ethical aspects

This study is a retrospective longitudinal cohort analysis based on data from physical records, documents, and free-text notes obtained

from a reference hospital in the region. Data collection occurred over 3 months, from April to June 2023. The sample included medical records of patients admitted to the adult ICU at the reference hospital who utilized medical devices during their hospitalization.

The study adhered to the guidelines of the Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement (13).

Ethical protocols were strictly followed to ensure the confidentiality of the collected data and protect participants from potential harm. Ethical approval was granted by the Research Ethics Committee of Fundação Hospital de Clínicas Gaspar Viana (approval number: 5,991,542), in compliance with Resolution 196/96 of the Brazilian National Health Council.

2.2 Selection of participants

The study included adult patients admitted to ICUs I and II who utilized medical devices during their hospitalization. Inclusion criteria comprised complete, legible, and finalized medical records of patients aged 18 years or older, of both sexes, admitted between 1 January 2021 and 31 December 2022. Medical records that were incomplete, illegible, or lacked conclusions were excluded. The patient selection process leading to the final study population is depicted in the flowchart below (Figure 1).

2.3 MDRPI case definition


In 2016, the National Pressure Ulcer Advisory Panel updated its definition of pressure injury (PI), describing it as localized damage to the skin and/or underlying soft tissue, typically over a bony prominence or related to the use of a medical device or another object. Medical device-related pressure injuries (MDRPIs) usually adopt the shape of the device involved and should be classified according to the existing PI classification system (3).

2.4 Data collection

The data collection process involved transcribing information from the medical record into an assessment form with pre-formulated questions. This form served as a guide for the research.

The eligibility criteria were based on the selection of cases in adult ICUs I and II. The cohort's time zero was defined by hospitalization data, and the delta-time (ΔT) corresponded to the period from hospitalization data to the stage of cure or death for those hospitalized. The time sequence continued until the end.

Subsequently, the data were organized in Excel 2019 format with 60 variables added to the form, referring to sociodemographic and clinical-epidemiological data. The variables extracted from the form were: alphanumeric medical record number (item 1), age (item 2), sex (item 3), length of stay (item 4), pulmonary arterial hypertension



(item 5), systemic arterial hypertension (SAH) (item 6), diabetes mellitus (DM) (item 7), obesity (item 8), heart disease (item 9), congestive heart failure (CHF) (item 10), acute myocardial infarction (AMI) (item 11), and arrhythmia (item 12). The following medical conditions are listed: acute renal failure (ARF) (item 13), chronic kidney disease (CKD) (item 14), autoimmune disease (item 15), stroke (item 16), cancer (CA) (item 17), multimorbidities (item 18), infectious disease (item 19), multi-diseases (item 20), alcoholism (item 21), former alcoholic (item 22), smoker (item 23), former smoker (item 24), and allergy to medication (item 25). The patient has reported allergy to product (item 26), pulmonary arterial obstructive disease (PAOD) (item 27), osteoporosis (item 28), pneumopathy (item 29), hypothyroidism (item 30), hyperthyroidism (item 31), benign prostatic hyperplasia (item 32), Down syndrome (item 33), chronic obstructive pulmonary disease (COPD) (item 34), and asthma (item 35), as well as anxiety (item 36). The following medical conditions are mentioned in the text: schizophrenia (item 37), gastritis (item 38), drug use (item 39), endocrinopathy (item 40), cirrhosis (item 41), rheumatic fever (item 42), Chagas disease (item 43), hepatitis B (item 44), hepatitis C (item 45), Human Immunodeficiency Virus (HIV) (item 46), Herpes (item 47), Syphilis (item 48), tuberculosis (TB) (item 49), and *Klebsiella pneumoniae* carbapenemase (KPC) (item 50). The following items were

mentioned in the text: streptococcus maltophilia (item 51), invasive ventilation (item 52), monitoring of pressure sources and skin friction (item 53), Braden scale (item 54), peripheral venous access (PVA) (item 55), Nasogastric Tube (NGT) (item 56), Central Venous Catheter (CVC) (item 57), Orotracheal Tube (OTT) (item 58), Bladder Indwelling Probe (BIP) (item 59), and Bladder Relief Probe (BRP) (item 60). The following medical items were used: Nasal Catheter (NC) (item 61), Nasoenteral Tube (ENS) (item 62), Double-Lumen Catheter (DLM) (item 63), drain (item 64), macro nebulization (item 65), Tracheostomy (TQT) (item 66), Pulse Oximeter (PO) (item 67), Invasive Blood Pressure (IBP) (item 68), Non-Rebreathing Mask (NRM) (item 69), pacemaker (item 70), and Ventricular Arterial Shunt (VAS) (item 71). The patient's condition was assessed based on several factors including peripheral perfusion (items 72 and 73), urinary stream (item 74), anuria (item 75), oliguria (item 76), complications during hospitalization (item 77), type of complication (item 78), urinary elimination (items 79–81), hematuria (item 82), lumps (item 83), and urinary urgency (item 84). The following items are included in this list: ureteroileostomy (item 85), absent intestinal elimination (item 86), normal intestinal elimination (item 87), elimination of intestinal diarrhea (item 88), hematochezia (item 89), melena (item 90), and constipation (item 91). The list aims to provide a comprehensive overview of mobility levels: room air (item 92), oxygen therapy (item 93), intubated (item 94), tracheostomized (item 95), conscious (item 96), oriented (item 97), disoriented (item 98), torpid (item 99), sedated (item 100), and agitated (item 101). The patient's condition is described as follows: item 102 indicates that they are bedridden, item 103 indicates that they walk with assistance, item 104 indicates that they are restricted to bed, and item 105 indicates that they are able to walk. Additional information includes the patient's oximetry value (item 114), Braden scale score (item 115), and number of medications taken during hospitalization (item 116).

The Braden Scale is a tool used in intensive care units to assess the risk of pressure injuries in critical patients. Nurses use this tool to record the patient's risk level and take preventative measures to promote effective treatment and greater patient comfort. The scale consists of six subscales for assessing six variables: Sensory Perception, Moisture, Activity, Mobility, Nutrition, and Friction and Shear. The subscales are scored on a scale of 1 to 4, with the exception of the Friction and Shear variable, which is scored on a scale of 1 to 3.

2.5 Statistical procedures

This study compared patients with MDRPI (exposed group) and without MDRPI (unexposed group). The comparative analyses included patient demographics, presence of comorbidities, hospitalization characteristics, types of medical devices, and lesion stages in both groups.

Data were organized in Microsoft Excel (version 2019) and analyzed using Jamovi software (version 2.3.28). Chi-square and Fisher's exact tests ($L \times C$ contingency table) were performed to evaluate the independence between categorical variables. Odds ratios (ORs) and their corresponding confidence intervals were calculated for variables with statistical significance ($p \leq 0.05$), comparing the MDRPI and non-MDRPI groups. Results were summarized and presented in tables.

Numerical variables underwent the Kolmogorov–Smirnov test to evaluate normality and were subsequently analyzed using the Mann–Whitney *U*-test due to their non-parametric distribution.

Binary logistic regression analysis was conducted to determine the relationship between MDRPI (dependent variable) and various independent variables. Both univariate and multivariate regression models were employed to identify factors significantly associated with MDRPI development.

Survival analysis was performed using the Kaplan–Meier method, considering the time from the initiation of hospitalization to either discharge or death, and accounting for variations related to device type, hospitalization reason, comorbidities, and treatment type. These outcomes were further analyzed with the Statistical Package for the Social Sciences (SPSS). The statistical significance level adopted for all analyses was set at 0.05.

3 Results

This study analyzed 603 medical records to identify the profile and factors associated with Medical Device-Related Pressure Injuries (MDRPI) among patients admitted to the Intensive Care Unit (ICU) of a metropolitan hospital during 2021 and 2022. Out of these records, 31 patients (5.14%) developed MDRPI, while 572 patients (94.86%) did not.

Initially, the epidemiological profile of the sample was characterized through bivariate analysis of 109 categorical variables. Of the total patients, 62.85% (379) were female, and 37.15% (224) were male. Among the sample, 15.26% (92) had medication allergies, and 0.50% (3) had product allergies. Regarding substance use, 14.59% (88) were alcoholics, and 23.71% (143) were former alcoholics. Additionally, 13.60% (82) were smokers, and 34.83% (210) were former smokers.

The epidemiological characteristics of the 603-patient cohort revealed that 219 individuals (36.32%) had diabetes mellitus and 449 (74.46%) had systemic arterial hypertension. Acute myocardial infarction was present in 12 patients (1.99%), heart disease in 89 (14.76%), pulmonary obstructive arterial disease in 1 (0.17%), osteoporosis in 5 (0.83%), hypo- or hyperthyroidism in 6 (1.00%), pulmonary arterial hypertension in 1 (0.17%), benign prostatic hyperplasia in 1 (0.17%), and Down syndrome in 1 (0.17%). Other comorbidities included chronic obstructive pulmonary disease (COPD; 17.00%), acute renal failure (1.49%), chronic heart failure (5.64%), asthma (1.00%), chronic kidney disease (7.30%), stroke (0.33%), arrhythmia (1.82%), anxiety (0.50%), schizophrenia (0.17%), obesity (1.82%), gastritis (0.17%), cancer (1.49%), autoimmune disease (0.66%), endocrinopathy (0.17%), cirrhosis (0.33%), rheumatic fever (0.17%), and multimorbidity (65.67%).

Table 1 shows the incidence of infectious conditions: other infectious diseases in 26 patients (4.31%), Chagas disease in 7 (1.16%), hepatitis B in 4 (0.66%), hepatitis C in 1 (0.17%), HIV in 9 (1.49%), herpes in 4 (0.66%), syphilis in 2 (0.33%), tuberculosis in 1 (0.17%), carbapenem-resistant *Klebsiella pneumoniae* (KPC) in 1 (0.17%), *Stenotrophomonas maltophilia* in 1 (0.17%), and multiple concurrent infections in 3 (0.50%). In the bivariate comparison between MDRPI carriers and non-carriers, systemic arterial hypertension ($p < 0.01$; OR 0.298; 95% CI 0.144–0.619), COPD ($p = 0.019$; OR 5.57; 95% CI

1.11–28.0), and multimorbidity ($p = 0.003$; OR 5.17; 95% CI 1.55–17.2) were significantly associated with the occurrence of MDRPI.

Table 2 summarizes hospitalization-related variables. Invasive mechanical ventilation was required by 49.42% of patients, while pressure-and-friction monitoring and Braden scale assessments were each performed in 59.54% of cases. The most frequently used medical devices were indwelling bladder catheters ($n = 378$; 62.69%), peripheral venous access ($n = 347$; 57.55%), orotracheal tubes ($n = 301$; 49.92%), nasogastric tubes ($n = 285$; 47.26%), and central venous catheters ($n = 257$; 42.62%). Additional devices included double-lumen catheters (26%), surgical drains ($n = 187$; 31.01%), macronebulization ($n = 51$; 8.46%), tracheostomies ($n = 41$; 6.80%), pulse oximeters ($n = 72$; 11.94%), invasive arterial pressure monitors ($n = 76$; 12.60%), non-rebreathing masks ($n = 5$; 0.83%), pacemakers ($n = 4$; 0.66%), and vasoactive drug infusions ($n = 7$; 1.16%).

Physiological assessments showed that 390 patients (64.68%) had adequate peripheral perfusion, whereas 173 (28.69%) had decreased perfusion. Urinary output patterns were normal in 366 (60.70%), anuric in 134 (22.22%), decreased stream in 42 (6.97%), oliguria in 2 (0.33%), choluric output in 5 (0.83%), and via cystostomy in 5 (0.83%). Hematuria occurred in 83 patients (13.76%), urinary urgency in 1 (0.17%), and ureteroileostomy in 1 (0.17%). Intestinal elimination was absent in 462 (76.62%), normal in 71 (11.77%), diarrheal in 19 (3.15%), hematochezia in 1 (0.17%), melena in 1 (0.17%), and constipation in 14 (2.32%).

At assessment, 210 patients (34.83%) breathed room air, 141 (23.38%) received supplemental oxygen, 236 (39.14%) were intubated, and 16 (2.65%) were tracheostomized. Neurologically, 46 (7.63%) were fully conscious, 199 (33.00%) oriented, 11 (1.82%) disoriented, 50 (8.29%) drowsy, 235 (38.97%) sedated, and 4 (0.66%) agitated. Mobility status showed 158 patients (26.20%) bedridden, 2 (0.33%) ambulating with assistance, 441 (73.13%) restricted to bed, and 3 (0.50%) walking independently. Nutritional status was normal in 28.86%, obese in 10.28%, overweight in 6.97%, experiencing weight loss in 6.30%, underweight in 0.83%, and malnourished in 14.10% of patients. Skin assessment revealed normal coloration in 31.84%, jaundice in 1.99, and 63.85% were classified as hypocaloric.

When comparing MDRPI carriers and non-carriers, bivariate analysis identified several significant associations. Monitoring of pressure and friction sources ($p = 0.005$; OR = 0.354; 95% CI, 0.166–0.753) and Braden scale assessments ($p = 0.005$; OR = 0.354; 95% CI, 0.166–0.753) were both protective. In contrast, use of an orotracheal tube ($p < 0.001$; OR = 7.34; 95% CI, 2.54–21.20), an indwelling bladder catheter ($p < 0.001$), a nasogastric tube ($p < 0.001$; OR = 6.28; 95% CI, 2.38–16.60), and tracheostomy ($p < 0.001$; OR = 5.68; 95% CI, 2.36–13.70) were all associated with increased MDRPI risk. Pulse oximetry monitoring also appeared protective ($p = 0.035$; OR = 0.110; 95% CI, 0.00663–1.81).

Among physiological parameters, good peripheral perfusion reduced MDRPI risk ($p < 0.001$; OR = 0.241; 95% CI, 0.111–0.521), whereas decreased perfusion did not reach statistical significance ($p = 0.13$; OR = 2.46; 95% CI, 1.19–5.09). Urinary elimination via cystostomy was significantly linked to MDRPI ($p < 0.001$), and diarrheal elimination increased risk ($p = 0.033$; OR = 3.72; 95% CI, 1.02–13.5), while normal intestinal elimination showed only a marginal association ($p = 0.055$; OR = 2.32; 95% CI, 0.959–5.59). Breathing room air was protective ($p = 0.009$; OR = 0.263; 95% CI, 0.908–0.763), whereas intubation increased risk ($p < 0.001$; OR = 3.49;

TABLE 1 Bivariate model for epidemiological factors associated with MDRPI in patients hospitalized in an intensive care unit of a hospital in the Brazilian Amazon in 2021 and 2022.

| Epidemiological variables | Without MDRPI 572 | % | With MDRPI 31 | % | Total 603 | % | p-value | OR | CI 95% | |
|---------------------------------|-------------------|-------|---------------|-------|-----------|-------|-----------|-------|--------|-------|
| Masculine | 212 | 37.06 | 12 | 38.71 | 224 | 37.15 | *0.813 | | | |
| Drug allergy | 86 | 15.03 | 6 | 19.35 | 92 | 15.26 | *0.515 | | | |
| Product allergy | 3 | 0.52 | 0 | 0.00 | 3 | 0.50 | ˆ0.686 | | | |
| Alcoholism | 85 | 14.86 | 3 | 9.68 | 88 | 14.59 | ˆ0.426 | | | |
| Former alcoholic | 137 | 23.95 | 6 | 19.35 | 143 | 23.71 | *0.558 | | | |
| Smoker | 80 | 13.99 | 2 | 6.45 | 82 | 13.60 | ˆ0.233 | | | |
| Former smoker | 197 | 34.44 | 13 | 41.94 | 210 | 34.83 | *0.394 | | | |
| Diabetes mellitus | 209 | 36.54 | 10 | 32.26 | 219 | 36.32 | *0.629 | | | |
| Hypertension | 434 | 75.87 | 15 | 48.39 | 449 | 74.46 | * < 0.001 | 0.298 | 0.144 | 0.619 |
| AMI | 12 | 2.10 | 0 | 0.00 | 12 | 1.99 | ˆ0.415 | | | |
| Cardiopathy | 86 | 15.03 | 3 | 9.68 | 89 | 14.76 | ˆ0.413 | | | |
| PAOD | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Osteoporosis | 5 | 0.87 | 0 | 0.00 | 5 | 0.83 | ˆ0.801 | | | |
| Pneumopathy | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Hypothyroidism | 6 | 1.05 | 0 | 0.00 | 6 | 1.00 | ˆ0.567 | | | |
| Hyperthyroidism | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Pulmonary arterial hypertension | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Benign prostatic hyperplasia | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Down's syndrome | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| COPD | 7 | 1.22 | 2 | 6.45 | 9 | 1.49 | ˆ0.019 | 5.57 | 1.11 | 28 |
| ARF | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| CHF | 31 | 5.42 | 3 | 9.68 | 34 | 5.64 | ˆ0.317 | | | |
| Asthma | 6 | 1.05 | 0 | 0.00 | 6 | 1.00 | ˆ0.567 | | | |
| CKD | 40 | 6.99 | 4 | 12.90 | 44 | 7.30 | ˆ0.218 | | | |
| Stroke | 2 | 0.35 | 0 | 0.00 | 2 | 0.33 | ˆ0.742 | | | |
| Arrhythmia | 11 | 1.92 | 0 | 0.00 | 11 | 1.82 | ˆ0.436 | | | |
| Anxiety | 3 | 0.52 | 0 | 0.00 | 3 | 0.50 | ˆ0.686 | | | |
| Schizophrenia | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Obesity | 10 | 1.75 | 1 | 3.23 | 11 | 1.82 | ˆ0.549 | | | |
| Gastritis | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |

(Continued)

TABLE 1 (Continued)

| Epidemiological variables | Without MDRPI 572 | % | With MDRPI 31 | % | Total 603 | % | <i>p</i> -value | OR | CI 95% | |
|---------------------------|-------------------|-------|---------------|-------|-----------|-------|-----------------|------|--------|------|
| Here | 9 | 1.57 | 0 | 0.00 | 9 | 1.49 | ˆ0.482 | | | |
| Autoimmune disease | 4 | 0.70 | 0 | 0.00 | 4 | 0.66 | ˆ0.64 | | | |
| Drug user | 6 | 1.05 | 0 | 0.00 | 6 | 1.00 | ˆ0.567 | | | |
| Endocrinopathy | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Cirrhosis | 2 | 0.35 | 0 | 0.00 | 2 | 0.33 | ˆ0.742 | | | |
| Rheumatic fever | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Multimorbidities | 368 | 64.34 | 28 | 90.32 | 396 | 65.67 | *0.003 | 5.17 | 1.55 | 17.2 |
| Infectious disease | 25 | 4.37 | 1 | 3.23 | 26 | 4.31 | ˆ0.76 | | | |
| Chagas | 7 | 1.22 | 0 | 0.00 | 7 | 1.16 | ˆ0.536 | | | |
| Hepatitis B | 4 | 0.70 | 0 | 0.00 | 4 | 0.66 | ˆ0.64 | | | |
| Hepatitis C | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| HIV | 9 | 1.57 | 0 | 0.00 | 9 | 1.49 | ˆ0.482 | | | |
| Herpes | 4 | 0.70 | 0 | 0.00 | 4 | 0.66 | ˆ0.64 | | | |
| Syphilis | 1 | 0.17 | 1 | 3.23 | 2 | 0.33 | ˆ0.004 | 19.0 | 1.16 | 312 |
| Also | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| KPC | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Maltophilia streptococcus | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Multidiseases | 3 | 0.52 | 0 | 0.00 | 3 | 0.50 | ˆ0.686 | | | |

Source: Authors' research. The chi-square test, for values less than 5, or Fisher's exact test was used. *The chi-square. ˆ Fisher's.

TABLE 2 Bivariate model for hospitalization factors associated with MDRPI in patients hospitalized in an intensive care unit of a hospital in the Brazilian Amazon in 2021 and 2022.

| International variables | Without MDRPI 572 | % | With MDRPI 31 | % | Total 603 | % | p-value | OR | CI 95% | |
|--------------------------------------------------|-------------------|-------|---------------|-------|-----------|-------|-----------|-------|---------|-------|
| Invasive ventilation | 278 | 48.60 | 20 | 64.52 | 298 | 49.42 | *0.084 | | | |
| Monitoring sources of skin pressure and friction | 348 | 60.84 | 11 | 35.48 | 359 | 59.54 | *0.005 | 0.354 | 0.166 | 0.753 |
| Performed Braden scale | 348 | 60.84 | 11 | 35.48 | 359 | 59.54 | *0.005 | 0.354 | 0.166 | 0.753 |
| Peripheral venous access | 332 | 58.04 | 15 | 48.39 | 347 | 57.55 | ˆ0.289 | | | |
| Nasogastric tube | 34 | 5.94 | 0 | 0.00 | 34 | 5.64 | ˆ0.162 | | | |
| Central venous catheter | 239 | 41.78 | 18 | 58.06 | 257 | 42.62 | *0.074 | | | |
| Orotracheal tube | 274 | 47.90 | 27 | 87.10 | 301 | 49.92 | * < 0.001 | 7.34 | 2.54 | 21.2 |
| Indwelling bladder catheter | 353 | 61.71 | 25 | 80.65 | 378 | 62.69 | *0.034 | 2.58 | 1.04 | 6.4 |
| Bladder relief probe | 6 | 1.05 | 0 | 0.00 | 6 | 1.00 | ˆ0.567 | | | |
| Nasal catheter | 124 | 21.68 | 11 | 35.48 | 135 | 22.39 | *0.072 | | | |
| Nasoenteral tube | 259 | 45.28 | 26 | 83.87 | 285 | 47.26 | * < 0.001 | 6.28 | 2.38 | 16.6 |
| Double lumen catheter | 174 | 30.42 | 13 | 41.94 | 187 | 31.01 | *0.177 | | | |
| Drain | 48 | 8.39 | 3 | 9.68 | 51 | 8.46 | ˆ0.802 | | | |
| Macronebulization | 5 | 0.87 | 0 | 0.00 | 5 | 0.83 | ˆ0.601 | | | |
| Tracheostomy | 33 | 5.77 | 8 | 25.81 | 41 | 6.80 | * < 0.001 | 5.68 | 2.36 | 13.7 |
| Pulse oximeter | 72 | 12.59 | 0 | 0.00 | 72 | 11.94 | ˆ0.035 | 0.110 | 0.00663 | 1.81 |
| Invasive blood pressure | 74 | 12.94 | 2 | 6.45 | 76 | 12.60 | ˆ0.289 | | | |
| Non-rebreathing mask | 5 | 0.87 | 0 | 0.00 | 5 | 0.83 | ˆ0.601 | | | |
| Pacemaker | 4 | 0.70 | 0 | 0.00 | 4 | 0.66 | ˆ0.64 | | | |
| Vasoactive drugs | 7 | 1.22 | 0 | 0.00 | 7 | 1.16 | ˆ0.536 | | | |
| Good peripheral perfusion | 380 | 66.43 | 10 | 32.26 | 390 | 64.68 | * < 0.001 | 0.241 | 0.111 | 0.521 |
| Decreased peripheral perfusion | 158 | 27.62 | 15 | 48.39 | 173 | 28.69 | *0.013 | 2.46 | 1.19 | 5.09 |
| Decreased urinary stream | 40 | 6.99 | 2 | 6.45 | 42 | 6.97 | ˆ0.908 | | | |
| Anuria | 130 | 22.73 | 4 | 12.90 | 134 | 22.22 | ˆ0.2 | | | |
| Oliguria | 2 | 0.35 | 0 | 0.00 | 2 | 0.33 | ˆ0.742 | | | |
| Normal urinary elimination | 347 | 60.66 | 19 | 61.29 | 366 | 60.70 | *0.945 | | | |
| Choluric urinary elimination | 5 | 0.87 | 0 | 0.00 | 5 | 0.83 | ˆ0.601 | | | |
| Elimination of urinary cystostomy | 2 | 0.35 | 3 | 9.68 | 5 | 0.83 | ˆ < 0.001 | 30.5 | 4.90 | 190 |
| Hematuria | 17 | 2.97 | 1 | 3.23 | 18 | 2.99 | ˆ0.936 | | | |
| Groats | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |

(Continued)

TABLE 2 (Continued)

| International variables | Without MDRPI 572 | % | With MDRPI 31 | % | Total 603 | % | <i>p</i> -value | OR | CI 95% | |
|---------------------------------------|-------------------|-------|---------------|-------|-----------|-------|-----------------|-------|--------|-------|
| Urinary urgency | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Cutaneous ureteroileostomy | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Intestinal absent elimination | 445 | 77.80 | 17 | 54.84 | 462 | 76.62 | *0.003 | 0.347 | 0.166 | |
| Normal intestinal elimination | 64 | 11.19 | 7 | 22.58 | 71 | 11.77 | *0.055 | 2.32 | 0.959 | 5.59 |
| Elimination of intestinal diarrhea | 16 | 2.80 | 3 | 9.68 | 19 | 3.15 | ˆ0.033 | 3.72 | 1.02 | 13.5 |
| Hematochezia | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Melena | 1 | 0.17 | 0 | 0.00 | 1 | 0.17 | ˆ0.816 | | | |
| Constipation | 13 | 2.27 | 1 | 3.23 | 14 | 2.32 | ˆ0.713 | | | |
| Ambient air | 206 | 36.01 | 4 | 12.90 | 210 | 34.83 | ˆ0.009 | 0.263 | 0.908 | 0.763 |
| Oxygen therapy | 135 | 23.60 | 6 | 19.35 | 141 | 23.38 | *0.586 | | | |
| Intubated | 215 | 37.59 | 21 | 67.74 | 236 | 39.14 | * < 0.001 | 3.49 | 1.61 | 7.54 |
| Tracheostomized | 16 | 2.80 | 0 | 0.00 | 16 | 2.65 | ˆ0.345 | | | |
| Conscious | 36 | 6.29 | 10 | 32.26 | 46 | 7.63 | *0.012 | 0.386 | 0.178 | 0.834 |
| Oriented | 195 | 34.09 | 4 | 12.90 | 199 | 33.00 | ˆ0.015 | 0.286 | 0.0988 | 0.83 |
| Disoriented | 11 | 1.92 | 0 | 0.00 | 11 | 1.82 | ˆ0.436 | 0.775 | 0.0446 | 13.5 |
| Torporous | 49 | 8.57 | 1 | 3.23 | 50 | 8.29 | ˆ0.294 | | | |
| Sedated | 216 | 37.76 | 19 | 61.29 | 235 | 38.97 | *0.009 | 2.61 | 1.24 | 5.48 |
| Hectic | 3 | 0.52 | 1 | 3.23 | 4 | 0.66 | ˆ0.071 | 6.32 | 0.638 | 62.6 |
| Mobility level: bedridden | 145 | 25.35 | 13 | 41.94 | 158 | 26.20 | *0.048 | 0.316 | 0.0945 | 1.05 |
| Mobility level: Walks with assistance | 2 | 0.35 | 0 | 0.00 | 2 | 0.33 | ˆ0.742 | | | |
| Mobility level: restricted to bed | 413 | 72.20 | 28 | 90.32 | 441 | 73.13 | *0.028 | 3.57 | 1.07 | 11.9 |
| Mobility level: walks | 3 | 0.52 | 0 | 0.00 | 3 | 0.50 | ˆ0.686 | | | |
| Overweight | 38 | 6.64 | 4 | 12.90 | 42 | 6.97 | ˆ0.182 | | | |
| Obesity | 55 | 9.62 | 7 | 22.58 | 62 | 10.28 | *0.021 | 2.74 | 1.13 | 6.65 |
| Weight loss report | 35 | 6.12 | 3 | 9.68 | 38 | 6.30 | ˆ0.427 | | | |
| Low weight | 5 | 0.87 | 0 | 0.00 | 5 | 0.83 | ˆ0.601 | | | |
| Malnutrition | 79 | 13.81 | 6 | 19.35 | 85 | 14.10 | *0.388 | | | |
| Normoweight | 168 | 29.37 | 6 | 19.35 | 174 | 28.86 | *0.231 | | | |
| Hypocaloric | 364 | 63.64 | 21 | 67.74 | 385 | 63.85 | *0.643 | | | |
| Normocolored | 186 | 32.52 | 6 | 19.35 | 192 | 31.84 | *0.125 | | | |
| Jaundice | 11 | 1.92 | 1 | 3.23 | 12 | 1.99 | ˆ0.613 | | | |

Source: Authors' research. The chi-square test, for values less than 5, or Fisher's exact test was used. *The chi-square. ˆ Fisher's.

TABLE 3 Bivariate model for numerical variables associated with MDRPI in patients hospitalized in an intensive care unit of a hospital in the Brazilian Amazon in 2021 and 2022.

| Numerical factors | Total (603) | MDRPI (31) | Without MDRPI (572) | p-value |
|-----------------------------------------------------|-------------|------------|---------------------|---------|
| Age | | | | |
| Minimum Maximum | 18–105 | 28–93 | 18–105 | |
| Media | 63.71 | 67.12 | 63.67 | |
| Median | 66 | 70 | 66 | 0.131 |
| Standard deviation | 15,634 | 15.34 | 15.61 | |
| Length of stay | | | | |
| Minimum Maximum | 55–100 | 74–100 | 55–100 | |
| Media | 8.78 | 21.06 | 7.93 | |
| Median | 5.00 | 20 | 5 | <0.001 |
| Standard deviation | 9,678 | 16.27 | 8.52 | |
| Oximetry value | | | | |
| Minimum Maximum | 55–100 | 74–100 | 55–100 | |
| Media | 95.51 | 82.51 | 92.37 | |
| Median | 96 | 95 | 96 | 0.515 |
| Standard deviation | 3.99 | 32.63 | 17.56 | |
| Braden scale score | | | | |
| Minimum Maximum | 0–26 | 0–15 | 0–26 | |
| Media | 8,538 | 3,677 | 8,530 | |
| Median | 9.00 | 0 | 9 | <0.001 |
| Standard deviation | 75,628 | 5,224 | 7,607 | |
| Number of medications during hospitalization | | | | |
| Minimum Maximum | 0–50 | 7–50 | 0–50 | |
| Media | 14.33 | 21.90 | 13.94 | |
| Median | 12 | 18 | 12 | <0.001 |
| Standard deviation | 8,906 | 11.61 | 8,658 | |

Source: Table created in Excel; Statistical test carried out in the Statistical Package for Social Science for Windows (SPSS).

95% CI, 1.61–7.54). Finally, patient consciousness and mobility influenced MDRPI risk: oriented patients had lower risk ($p = 0.015$; OR = 0.286; 95% CI, 0.0988–0.830), sedated patients had higher risk ($p = 0.009$; OR = 2.61; 95% CI, 1.24–5.48), bed mobility was protective ($p = 0.048$; OR = 0.316; 95% CI, 0.0945–1.05), restriction to bed increased risk ($p = 0.028$; OR = 3.57; 95% CI, 1.07–11.9), and obesity was also a risk factor ($p = 0.021$; OR = 2.74; 95% CI, 1.74–6.65).

Mann–Whitney U-tests were applied to all continuous variables. Age did not differ significantly between MDRPI carriers and non-carriers ($p = 0.131$). The overall mean age was 63 ± 15.6 years (median 66; range 18–105). Among the 31 patients with MDRPI, mean age was 67 ± 15.3 years (median 70), and among those without MDRPI, it was 67 ± 15.3 years (median 70; range 28–93).

Length of stay ranged from 1 to 81 days (mean \pm SD: 8 ± 9 days; median 5) and was significantly longer in patients who developed MDRPI (mean \pm SD: 21 ± 18 days; median 20; range 5–81) than in those who did not (mean \pm SD: 7 ± 6 days; median 5; range 1–62; $p < 0.001$), indicating that prolonged hospitalization increases MDRPI risk.

Oxygen saturation averaged $95\% \pm 3.9$ (median 96%; range 55–100%) across all patients and did not differ significantly between

groups ($p = 0.515$). In the MDRPI group, saturation values ranged from 74 to 100% (mean 82%; median 95%), whereas in the non-MDRPI group, they ranged from 55 to 100% (mean 92%; median 96%).

Braden scale scores ranged from 0 to 26 points (mean \pm SD: 8 ± 7 ; median: 9). Among patients who developed MDRPI, scores ranged from 0 to 15 (mean \pm SD: 3 ± 5 ; median: 0), compared with a range of 0 to 26 (mean \pm SD: 8 ± 7 ; median: 9) in those without MDRPI ($p < 0.001$), confirming the Braden scale's predictive value in skin assessment and injury prevention.

The number of medications administered during hospitalization (Table 3) varied from 0 to 50. Patients who developed MDRPI received significantly more medications (range: 7–50; mean \pm SD: 21 ± 11 ; median: 18) than those without MDRPI (range: 0–50; mean \pm SD: 13 ± 8 ; median: 12; $p < 0.001$), indicating an association between polypharmacy and MDRPI risk.

Table 4 presents the multivariate logistic regression of factors independently associated with MDRPI. Chronic obstructive pulmonary disease emerged as the strongest risk factor ($p = 0.002$; OR 19.33; 95% CI 2.92–127.73), followed by orotracheal tube use ($p = 0.002$; OR 19.00; 95% CI –), nasal catheter use ($p = 0.011$; OR

TABLE 4 Final multivariate model for associated factors for MDRPI in patients hospitalized in an intensive care unit of a hospital in the Brazilian Amazon in 2021 and 2022.

| Variables | <i>p</i> -value | OR | CI 95% | |
|---------------------------------------|-----------------|---------|---------|----------|
| | | | Minimum | Maximum |
| Chronic obstructive pulmonary disease | 0.002 | 19.3256 | 2.92404 | 127.7263 |
| Orotracheal tube | 0.004 | 5.4812 | 1.70836 | 17.5865 |
| Nasal Catheter | 0.011 | 3.3297 | 1.31973 | 8.4008 |
| Length of stay | <0.001 | 1.0863 | 1.05026 | 1.1236 |
| Systemic arterial hypertension | 0.009 | 0.3155 | 0.13198 | 0.7543 |
| Braden scale score | 0.002 | 0.2211 | 0.08405 | 0.5816 |
| Invasive blood pressure | 0.025 | 0.1445 | 0.02652 | 0.7869 |
| Interception | <0.001 | 0.0178 | 0.00514 | 0.0614 |

Source: Authors' research. OR (Odds Ratio), IC (Confidence Interval). Model fit R^2 Nagelkerke 0.631.

3.33; 95% CI 1.32–8.40), and longer hospital stay ($p < 0.001$; OR 1.09; 95% CI 1.05–1.12). Protective predictors included systemic arterial hypertension ($p = 0.009$; OR 0.22; 95% CI 0.08–0.58), higher Braden scale scores ($p = 0.002$; OR 0.22; 95% CI 0.08–0.58), and invasive arterial pressure monitoring ($p = 0.025$; OR 0.14; 95% CI 0.27–0.79).

Survival analysis using Kaplan–Meier curves compared the time to discharge with the time of death among patients with MDRPI. The Breslow (generalized Wilcoxon) test showed a significant difference ($p = 0.007$), as did the log-rank (Mantel–Cox) test ($p = 0.041$) and the Tarone–Ware test ($p = 0.011$). Patients who were eventually discharged had a mean hospital stay of 17 days, whereas those who died remained hospitalized for a mean of 24 days. These findings indicate that MDRPI is associated with both prolonged hospitalization and increased mortality (Figure 2).

4 Discussion

This is the first retrospective cohort study conducted in the Amazon region to investigate factors associated with medical device-related pressure injuries (MDRPIs). It analyzed 109 numerical and categorical variables to characterize the profile of damage caused by medical devices in an intensive care unit. The study identified chronic obstructive pulmonary disease (COPD), use of orotracheal tubes (OTT), nasal catheters (NC), and length of hospital stay as risk factors. Conversely, systemic arterial hypertension (SAH), Braden scale score, and invasive arterial pressure monitoring were found to be protective predictors.

A study conducted in Nepal reported that hemodynamic instability and hypotension associated with comorbidities contribute significantly to MDRPI development among COPD patients (14). Additionally, a cross-sectional study involving 145 individuals with COPD demonstrated that disease exacerbations contribute to alveolar hypoxia, hypoxemia, and decreased oxygen saturation. These conditions weaken patients physically, increasing skin and tissue vulnerability (15). However, difficulties were encountered in locating robust literature specifically connecting COPD with MDRPI development. Further research is thus required to more clearly delineate risk factors contributing to MDRPI among COPD patients.

The existing literature consistently highlights medical device use as a risk factor for developing pressure injuries compared to patients

without medical devices (16). In this study, OTT and NC emerged as significant predictors of MDRPI. Similarly, a prospective study conducted in Australia identified nasal catheters and endotracheal tubes as major causes of MDRPI, accounting for 21 and 13 cases, respectively, emphasizing their prevalence among ICU patients (17).

Length of hospital stay was also identified as a significant risk factor in this cohort. This finding aligns with the cross-sectional epidemiological study by Galetto et al. (9), in which prolonged hospitalization correlated significantly with MDRPI occurrence. Their study of 93 patients revealed that prolonged stays with therapeutic and monitoring devices increased MDRPI risk, resulting in extended hospitalization durations. This underscores the need for improved preventive strategies, especially in intensive care units.

Interestingly, systemic arterial hypertension was identified as a protective predictor in this study's multivariate analysis. This result contradicts the prevailing literature, which typically characterizes pre-existing chronic conditions as intrinsic risk factors for pressure injury development in critically ill patients (18, 19). Cox and Roche (20), in their retrospective analysis of 306 ICU patients, reported hypotension and vasopressor use as notable risk factors for injury formation. There are currently no references suggesting that hypertension or vasodilator treatment is protective. We hypothesize that the protective effect identified here may be attributed to vasodilator treatment in hypertensive patients; however, this hypothesis remains untested in the current literature.

The Braden scale was also identified as a protective predictor in our retrospective cohort. The Braden scale is an established tool integrated into Nursing Care Systematization (NCS) practices for the prevention of pressure injuries (PI), assessing sensory perception, moisture, activity, mobility, nutrition, friction, and shear (21). Padula et al. (22) and Hanonu and Karadag (23) similarly demonstrated that lower Braden scores correlate significantly with higher MDRPI risk. Hanonu and Karadag specifically observed that patients with low Braden scale scores had a 1.81-fold increased risk of developing MDRPI in ICU settings.

Contrary to expectations, invasive arterial pressure (IAP) monitoring was also classified as protective against MDRPI. This finding diverges from previous studies, such as Reisdorfe's (24) evaluation of ICU patients, where invasive arterial catheters were linked directly to injury formation. Reisdorfe observed that 8.5% of patients who used arterial punctures developed MDRPI, concluding




FIGURE 2

Survival analysis of patients with pressure injuries related to medical devices until the stage of discharge or death in patients admitted to an intensive care unit in a metropolitan region of the Amazon during the COVID-19 pandemic, Pará, Brazil, 2023. Source: Authors' research. Statistical Package for the Social Sciences, 2023. Breslow (Generalized Wilcoxon) (0.007), Long hank (Mentel cox) (0.041), and Tarone-ware (0.011).

that invasive monitoring devices present significant risks. Similarly, Ferreira et al. (25) highlighted the importance of nursing management in preventing MDRPIs associated with radial arterial catheters, which contrasts with the protective result observed in our cohort. Therefore, further research is needed to clarify this relationship.

The overall scarcity of studies specifically addressing MDRPI highlights the necessity for more detailed research. Further studies are essential to refine the classification systems recommended by the National Pressure Ulcer Advisory Panel (3) and accurately define causative and preventive factors.

Adherence to manufacturers' guidelines for medical devices is essential for patient safety, treatment effectiveness, and MDRPI prevention. A retrospective qualitative study analyzing NOTIVISA data from 2007 to 2016 identified adverse events linked to inappropriate medical device handling by healthcare professionals, primarily due to insufficient knowledge or training (26, 27). Maia et al. (28) similarly highlighted systemic flaws in patient care, documenting 63,933 adverse events in NOTIVISA from 2014 to 2016, including 417 fatalities. These findings emphasize the critical importance of systematic reporting and improved healthcare practices.

In Brazil, studies addressing healthcare-related adverse events remain limited (28), particularly in the Amazon region, where incomplete patient records complicate accurate notification and reporting of such incidents. Strengthening notification systems within patient safety units is crucial to enhance preventive measures and patient care quality. Moreover, medical device quality significantly influences care outcomes. Previous qualitative-quantitative research indicates that high-quality medical devices are essential to prevent adverse events, minimize risks for patients and healthcare professionals, and avoid device-related failures (29).

The main limitation of this study is its retrospective design, relying exclusively on secondary data extracted from medical records. Such

dependence introduces inherent risks affecting result validity, including incomplete, inaccurate, or illegible documentation and associated selection or classification biases. Furthermore, analyses were constrained by documented variables, preventing control for unrecorded confounding factors. These limitations, compounded by the small number of patients with MDRPI ($n = 31$) and a single-center setting during the COVID-19 pandemic, restrict statistical robustness and generalizability of the findings.

5 Conclusion

Of the 603 medical records analyzed, 62.85% of patients were female. The primary predictors of MDRPI identified in this study align closely with the existing literature. Specifically, chronic obstructive pulmonary disease, orotracheal tube use, nasal catheter use, and prolonged hospital stays emerged as significant risk factors, whereas systemic arterial hypertension, higher Braden scale scores, and invasive arterial pressure monitoring were identified as protective factors.

This cohort did not exhaustively address all aspects associated with MDRPI. Therefore, future prospective studies are strongly recommended. The limited literature available in Brazil highlights an urgent need for further research to strengthen evidence-based strategies for preventing MDRPI in intensive care settings, thus positively impacting patient safety, care quality, and reducing mortality.

As the first study of its kind in our region, it confirmed that local risk factors for MDRPI are consistent with global findings, despite the greater vulnerability related to social and health determinants. Improving nursing care and working conditions in ICUs is essential to mitigate MDRPI risk. The findings presented

here can guide continuous professional development for nursing teams and inform educational discussions within academic nursing programs.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by Ethics and Research Committee of Fundação Hospital de Clínicas Gaspar Viana (opinion no. 5,991,542) / Belém-PA. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

VS: Resources, Funding acquisition, Formal analysis, Writing – original draft, Conceptualization, Data curation, Methodology, Visualization, Investigation. DF: Formal analysis, Methodology, Conceptualization, Visualization, Resources, Writing – original draft, Investigation, Data curation. GM: Writing – original draft, Resources, Visualization, Formal analysis, Methodology, Data curation, Investigation. RM: Formal analysis, Writing – original draft, Visualization, Resources, Methodology, Validation, Investigation, Conceptualization. NA: Methodology, Writing – original draft, Formal analysis, Visualization, Investigation, Resources, Data curation, Validation. TS: Validation, Visualization, Methodology, Data curation, Formal analysis, Conceptualization, Resources, Investigation, Writing – original draft. MS: Formal analysis, Writing – original draft, Supervision, Software, Visualization, Validation, Methodology, Resources, Writing – review & editing, Investigation. DL: Visualization, Data curation, Methodology, Resources, Writing – review & editing, Validation, Formal analysis, Writing – original draft, Supervision. SS: Writing – original draft, Methodology, Visualization, Investigation, Data

curation, Validation, Resources, Formal analysis. YR: Resources, Validation, Writing – original draft, Methodology, Visualization, Formal analysis, Supervision. DS: Visualization, Project administration, Funding acquisition, Formal analysis, Validation, Data curation, Resources, Supervision, Methodology, Writing – review & editing, Writing – original draft, Investigation. LL: Writing – original draft, Investigation, Visualization, Software, Resources, Validation, Project administration, Funding acquisition, Supervision, Data curation, Methodology, Writing – review & editing, Conceptualization.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. The funding for this study was provided by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Instituto Evandro Chagas (IEC), and Fundação Amazônia de Amparo a Estudos e Pesquisas (FAPESPA).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The authors declare that no Gen AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Cardoso Metwaly Mohamed AY, Pantaleão Souza TM, Garcia PC, Nogueira PC. Incidence of pressure injury and nursing care time in intensive care. *Revista Estima*. (2020) 18:849. doi: 10.30886/estima.v18.849_IN
- Cavalcante EO, Kamada I. Lesão por pressão relacionada a dispositivos médicos: frequência e fatores associados. *Revista Estima*. (2022) 20:e0322. doi: 10.30886/estima.v20.1146_PT
- National Pressure Ulcer Advisory Panel (2016) Announces a change in terminology from pressure ulcer to pressure injury and updates the stages of pressure injury. Available online at: <https://www.npuap.org/national-pressure-ulcer-advisory-panel-npuap-announces-a-change-in-terminology-from-pressure-ulcer-to-pressure-injury-and-updates-the-stages-of-pressure-injury/>. (Accessed November 29, 2016)
- Soldera D, Balbinot Reis Gironi J, de Almeida S, Hammerschmidt K, Amante LN, Neta LO, et al. Lesões por pressão relacionadas a dispositivos médicos na prática clínica de enfermeiros. *Enferm Foco*. (2021) 12:3427. doi: 10.21675/2357-707X.2021.v12.n2.3427
- Fecher GC, Alves WFP, Menezes DCS, Bastos MP. Redução na incidência de lesão por pressão, em um hospital privado. *Nursing*. (2022) 25:7804–13. doi: 10.36489/nursing.2022v25i288p7804-7813
- dos Santos Sokem JA, Watanabe EAMT, Ferreira AM, Siqueira LDC, Coelho M d MF, Bergamaschi FPR. Conhecimento da equipe de enfermagem sobre lesão por pressão. *Estima*. (2021) 19:e2521. doi: 10.30886/estima.v19.1129_PT
- Bigoni A, Malik AM, Tasca R, Carrera MBM, Schiesari LMC, Gambardella DD, et al. Brazil's health system functionality amidst of the COVID-19 pandemic: an analysis of resilience. *Lancet Reg Health Am*. (2022) 10:100222. doi: 10.1016/j.lana.2022.100222
- Cavalcanti EO, Kamada I. Medical-device-related pressure injury on adults: an integrative review. *Texto Contexto Enferm*. (2020) 29:371. doi: 10.1590/1980-265x-tce-2018-0371
- Galetto SGDS, do Nascimento ERP, Hermida PMV, Busanello J, de Malfussi LBH, Lazzari DD. Medical device-related pressure injuries in critical patients: prevalence and

associated factors. *Rev Esc Enferm USP*. (2021) 55. doi: 10.1590/1980-220x-reuusp-2020-0397

10. Olshansky K. The 10 Most important questions concerning pressure ulcers and quality of care. *Adv Skin Wound Care*. (2008) 21:505–8. doi: 10.1097/01.ASW.0000323585.35228.4c

11. Coyer FM, Stotts NA, Blackman VS. A prospective window into medical device-related pressure ulcers in intensive care. *Int Wound J*. (2014) 11:656–64. doi: 10.1111/iwj.12026

12. Ministério da Saúde. Manual de Tecnovigilância: abordagens de vigilância sanitária de produtos para a saúde comercializados no Brasil. Brazil: Ministério da Saúde (2010).

13. Vandembroucke J, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. *PLoS Med*. (2007) 4:e297. doi: 10.1371/journal.pmed.0040297

14. Santos CNS, Oliveira GM, Cavichioli FCT, Nascimento Filho HM, Ferreira FA, Borges DTM. Lesão por pressão relacionada a dispositivos médicos: prevenção e fatores de risco associados. *Nursing*. (2021) 24:6480–6.

15. Sangroula P, Ghimire S, Srivastava B, Adhikari D, Dhonju K, Shrestha A, et al. Correlation of body mass index and oxygen saturation in chronic obstructive pulmonary disease patients at a tertiary Care Center in Nepal: a cross-sectional study. *Int J Chron Obstruct Pulmon Dis*. (2023) 18:1413–8. doi: 10.2147/COPD.S412118

16. Black J, Kalowes P. Medical device-related pressure ulcers. *Chronic Wound Care Manag Res*. (2016) 3:91–9. doi: 10.2147/CWCMR.S82370

17. Barakat-Johnson M, Barnett C, Wand T, White K. Medical device-related pressure injuries: an exploratory descriptive study in an acute tertiary hospital in Australia. *J Tissue Viability*. (2017) 26:246–53. doi: 10.1016/j.jtv.2017.09.008

18. Oliveira LS, Melo AS, Campos LF, Lopes LES, Teixeira RMP, Jesus CVF, et al. Fatores de risco relacionados à lesão por pressão em pacientes COVID-19 em unidade de terapia intensiva: revisão integrativa. *Res Soc Dev*. (2023) 12:e6212842885. doi: 10.33448/rsd-v12i8.42885

19. Pedrosa IL, Silva MSML, Araújo AA, Schwanke CHA, DeCarli GA, Gomes I. Pressure ulcers in elders and in non-elders: a historical cohort study. *Online Braz J Nurs*. (2014) 13:111. doi: 10.5935/1676-4285.20144111

20. Cox J, Roche S. Vasopressors and development of pressure ulcers in adult critical care patients. *Am J Crit Care*. (2015) 24:501–10. doi: 10.4037/ajcc2015123

21. Park S-H, Choi Y-K, Kang C-B. Predictive validity of the Braden scale for pressure ulcer risk in hospitalized patients. *J Tissue Viability*. (2015) 24:102–13. doi: 10.1016/j.jtv.2015.05.001

22. Padula CA, Paradis H, Goodwin R, Lynch J, Hegerich-Bartula D. Prevention of medical device-related pressure injuries associated with respiratory equipment use in a critical care unit. *J Wound Ostomy Continence Nurs*. (2017) 44:138–41. doi: 10.1097/WON.0000000000000311

23. Hanonu S, Karadag A. A prospective, descriptive study to determine the rate and characteristics of and risk factors for the development of medical device-related pressure ulcers in intensive care units. *Ostomy Wound Manage*. (2016) 62:12–22.

24. Reisidorfer N. (2021) Lesão por pressão relacionada a dispositivos médicos em unidade de terapia intensiva: incidência, fatores de risco e atuação da enfermagem. *Revista de Enfermagem da UFSM*.

25. Ferreira ACG, Murakami BM, Bergamasco EC, dos Santos ER, Coelho FU d A, Lucinio NM, et al. Comparação de valores de pressão arterial invasiva média do paciente crítico em diferentes decúbitos. *Rev Soc Cardiol Estado Sao Paulo*. (2017) 27:25–8. doi: 10.29381/0103-8559/20172701S25-8

26. Oliveira CG, Rodas ACD. Tecnovigilância no Brasil: panorama das notificações de eventos adversos e queixas técnicas de cateteres vasculares. *Ciênc Saúde Colet*. (2017) 22:3247–57. doi: 10.1590/1413-812320172210.17612017

27. Rodrigues PCF, Souza JBde, Martorell LB, Freitas PH, Lopes LG. Olhar vigilante na qualidade dos produtos odontológicos: a importância da vigipós. *RBOL* (2015) 2:23 doi: 10.21117/rbol.v2i1.23

28. Maia CS, Freitas DRC, Gallo LG, Araújo WN. Notificações de eventos adversos relacionados com a assistência à saúde que levaram a óbitos no Brasil, 2014-2016. *Epidemiol Serv Saude*. (2018) 27:e2017320. doi: 10.5123/S1679-49742018000200004

29. Ramirez SS, Leandro KC, Feitoza-Silva M. O perfil de queixas técnicas relacionadas a equipamentos comercializados no Brasil e o impacto na segurança do paciente. *Rev Electron Comun Inf Inov Saude*. (2022) 16:946–57. doi: 10.29397/reciis.v16i4.3167